Alpha Tau Medical is a cutting-edge brand focused on the development and commercialization of a revolutionary cancer treatment called DaRT (Diffusing Alpha-Emitters Radiation Therapy). Founded in 2016 by CEO Uzi Sofer, Alpha Tau aims to bring this innovative alpha radiation technology to cancer patients worldwide. The treatment was invented by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University.

Alpha Tau has conducted extensive clinical trials, starting with a study on locally advanced and recurrent SCC cancers of the skin and head and neck. The results of this study were published in the prestigious International Journal of Radiation Oncology | Biology | Physics and received great enthusiasm from the medical community. Based on the positive outcomes, the FDA granted Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with certain types of cancer.

Alpha Tau is also actively involved in ongoing clinical and pre-clinical studies with esteemed medical and educational institutions worldwide. They are evaluating the use of Alpha DaRT technology for various cancer indications, such as breast, pancreas, lung, GBM, and prostate cancers, as well as exploring the potential of combining it with immunotherapies. With their mission to revolutionize solid tumor treatment, Alpha Tau aims to provide new options for cancer patients, including those with unresectable tumors, limited treatment options, and metastatic cancers.

Inspired by Marie Curie's belief in the power of scientific discoveries for the greater good of humanity, the Alpha Tau team is dedicated to rigorous research and strategic collaborations to unlock the full therapeutic potential of radium in cancer treatment